gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Excision repair cross-complementing rodent repair deficiency, complementation group 2

The nucleotide excision repair pathway is a mechanism to repair damage to DNA. The protein encoded by this gene is involved in transcription-coupled nucleotide excision repair and is an integral member of the basal transcription factor BTF2/TFIIH complex. The gene product has ATP-dependent DNA helicase activity and belongs to the RAD3/XPD subfamily of helicases. Defects in this gene can result in three different disorders, the cancer-prone syndrome xeroderma pigmentosum complementation group D, trichothiodystrophy, and Cockayne syndrome. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2008] (from NCBI)
Top mentioned proteins: XRCC1, ERCC1, HAD, AGE, XRCC3
Papers using XPD antibodies
Macromolecular dynamics in living cell nuclei revealed by fluorescence redistribution after photobleaching
Cooper Priscilla, In PLoS Biology, 2000
... In addition, full-length human XPD cDNA was cloned in-frame into pEGFP-N2 vector (Clontech).
Papers on XPD
Influence of XPC, XPD, XPF, and XPG gene polymorphisms on the risk and the outcome of acute myeloid leukemia in a Romanian population.
Lazar et al., Târgu-Mureş, Romania. In Tumour Biol, Feb 2016
UNASSIGNED: XPC, XPD, XPF, and XPG genes are implicated in the nucleotide excision repair (NER) system.
Association of the XPD and XRCC3 gene polymorphisms with oral squamous cell carcinoma in a Northeastern Brazilian population: A pilot study.
da Costa Miguel et al., Natal, Brazil. In Arch Oral Biol, Jan 2016
OBJECTIVE: to evaluate the association between XPD and XRCC3 polymorphisms and oral squamous cell carcinoma (OSCC).
A germline predictive signature of response to platinum chemotherapy in esophageal cancer.
Saggioro et al., Padova, Italy. In Transl Res, Jan 2016
Four gene variants of DNA repair machinery, 2 in ERCC1 (rs11615; rs3212986), and 2 in XPD (rs1799793; rs13181) were also studied.
Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy.
Berretta et al., Napoli, Italy. In Eur Rev Med Pharmacol Sci, Nov 2015
MATERIALS AND METHODS: A systematic literature search of the MEDLINE, EMBASE, and Cochrane databases was conducted to identify all clinical studies of any association between DPYD and 5-FU correlated to allelic status of 6 validated polymorphisms in five genes Dihydropyrimidine Dehydrogenase (DPYD), Thymidylate Synthase (TYMS), Glutathione S-Transferase (GSTP1), and DNA-repair genes (ERCC2 and XRCC1).
Predictive Value of Ercc1 and Xpd Polymorphisms for Clinical Outcomes of Patients Receiving Neoadjuvant Therapy: A Prisma-Compliant Meta-Analysis.
Qiang et al., Nanjing, China. In Medicine (baltimore), Sep 2015
Excision repair cross complementing 1 (ERCC1) and xeroderma pigmentosum group D (XPD) play important roles in the nucleotide excision repair (NER) pathway.
Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.
Kurzrock et al., San Diego, United States. In Cancer Treat Rev, Sep 2015
The Cancer Genome Atlas (TCGA) study revealed that there are numerous genomic aberrations in muscle-invasive urothelial carcinoma, such as TP53, ARID1A, PIK3CA, ERCC2, FGFR3, and HER2.
Association of chromosome 19 to lung cancer genotypes and phenotypes.
Marko-Varga et al., Shanghai, China. In Cancer Metastasis Rev, Jun 2015
Gene aberrations include translocation t(15, 19) (q13, p13.1) fusion oncogene BRD4-NUT, DNA repair genes (ERCC1, ERCC2, XRCC1), TGFβ1 pathway activation genes (TGFB1, LTBP4), Dyrk1B, and potential oncogenesis protector genes such as NFkB pathway inhibition genes (NFKBIB, PPP1R13L) and EGLN2.
ERCC2 polymorphisms and radiation-induced adverse effects on normal tissue: systematic review with meta-analysis and trial sequential analysis.
Dong et al., Changchun, China. In Radiat Oncol, 2014
BACKGROUND: The relationship between ERCC2 polymorphisms and the risk of radiotoxicity remains inconclusive.
Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer.
Zhu et al., Jinan, China. In Genet Mol Res, 2014
We performed a study to investigate the role of ERCC1 (rs11615, rs2298881, and rs3212986) and ERCC2 (rs13181, rs238406, and rs1799793) polymorphisms in the prognosis of gastric cancer.
Polymorphisms in DNA repair genes of XRCC1, XPA, XPC, XPD and associations with lung cancer risk in Chinese people.
Zhou et al., Tianjin, China. In Thorac Cancer, 2014
RESULTS: In single tag SNP analysis, XPA rs2808668, XPC rs2733533, and XPD rs1799787 were significantly associated with lung cancer susceptibility.
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.
Real et al., Madrid, Spain. In Nat Genet, 2013
A discovery exome sequencing screen (n = 17), followed by a prevalence screen (n = 60), identified new genes mutated in this tumor coding for proteins involved in chromatin modification (MLL2, ASXL2 and BPTF), cell division (STAG2, SMC1A and SMC1B) and DNA repair (ATM, ERCC2 and FANCA).
Global regulation of promoter melting in naive lymphocytes.
Casellas et al., Bethesda, United States. In Cell, 2013
Resting lymphocytes also limit the expression of the transcription factor IIH complex, including XPB and XPD helicases involved in promoter melting and open complex extension.
Structural visualization of key steps in human transcription initiation.
Nogales et al., Berkeley, United States. In Nature, 2013
Our structural analyses provide pseudo-atomic models at various stages of transcription initiation that illuminate critical molecular interactions, including how TFIIF engages Pol II and promoter DNA to stabilize both the closed pre-initiation complex and the open-promoter complex, and to regulate start--initiation complexes, combined with the localization of the TFIIH helicases XPD and XPB, support a DNA translocation model of XPB and explain its essential role in promoter opening.
A novel XPD mutation in a compound heterozygote; the mutation in the second allele is present in three homozygous patients with mild sun sensitivity.
Hanawalt et al., Israel. In Environ Mol Mutagen, 2012
A novel XPD mutation in a compound heterozygote; the mutation in the second allele is present in three homozygous patients with mild sun sensitivity.
No evidence of association between the synonymous polymorphisms in XRCC1 and ERCC2 and breast cancer susceptibility among nonsmoking Chinese.
Sun et al., Shenyang, China. In Gene, 2012
The data suggested that XRCC1 Pro206Pro and ERCC2 Arg156Arg do not substantially influence breast cancer susceptibility among nonsmoking Chinese. The two loci were at weak linkage disequilibrium.
A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera.
Guillem et al., Valencia, Spain. In Blood, 2012
A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera.
Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.
Lu et al., Shanghai, China. In Plos One, 2011
Data show the predictive role of xeroderma pigmentosum group D (XPD) polymorphisms/haplotype on non-small cell lung cancer (NSCLC) prognosis in inoperable advanced NSCLC patients treated with platinum-based chemotherapy.
Associations between XPD Asp312Asn polymorphism and risk of head and neck cancer: a meta-analysis based on 7,122 subjects.
Niu et al., Shiyan, China. In Plos One, 2011
XPD Asp312Asn polymorphism may not be a risk factor for developing head and neck cancer. [Meta-analysis]
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
Laurent-Puig et al., Villejuif, France. In J Clin Oncol, 2010
Twenty polymorphisms within the DPD, TS, MTHFR, ERCC1, ERCC2, GSTP1, GSTM1, GSTT1, and UGT1A1 genes were genotyped.
Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
Seymour et al., Leeds, United Kingdom. In J Clin Oncol, 2009
Ten polymorphisms were assessed: thymidylate synthase-enhancer region (TYMS-ER), thymidylate synthase 1494 (TYMS-1494), dihydropyrimidine dehydrogenase (DPYD), methylenetetrahydrofolate reductase (MTHFR), mutL homolog 1 (MLH1), UDP glucuronyltransferase (UGT1A1), ATP-binding cassette group B gene 1 (ABCB1), x-ray cross-complementing group 1 (XRCC1), glutathione-S-transferase P1 (GSTP1), and excision repair cross-complementing gene 2 (ERCC2).
share on facebooktweetadd +1mail to friends